Evolent Health - EVH Stock Forecast, Price & News

10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Evolent Health in the last twelve months. There are currently 1 hold rating and 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" EVH shares.
View EVH analyst ratings or view top-rated stocks.

10 brokers have issued 1 year target prices for Evolent Health's stock. Their EVH share price forecasts range from $32.00 to $59.00. On average, they predict the company's stock price to reach $47.70 in the next twelve months. This suggests a possible upside of 53.6% from the stock's current price.
View analysts price targets for EVH or view top-rated stocks among Wall Street analysts.

Evolent Health's stock was trading at $28.08 at the beginning of the year. Since then, EVH stock has increased by 10.6% and is now trading at $31.05.
View the best growth stocks for 2023 here.

Evolent Health saw a drop in short interest during the month of March. As of March 15th, there was short interest totaling 5,180,000 shares, a drop of 9.4% from the February 28th total of 5,720,000 shares. Based on an average daily volume of 974,800 shares, the short-interest ratio is presently 5.3 days.
View Evolent Health's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 3rd 2023.
View our EVH earnings forecast.

Evolent Health, Inc. (NYSE:EVH) released its quarterly earnings results on Wednesday, February, 22nd. The technology company reported ($0.04) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.02) by $0.02. The technology company had revenue of $382.43 million for the quarter, compared to analysts' expectations of $373.68 million. Evolent Health had a positive trailing twelve-month return on equity of 7.50% and a negative net margin of 1.42%.

ETFs with the largest weight of Evolent Health (NYSE:EVH) stock in their portfolio include Fidelity Digital Health ETF (FDHT), Invesco DWA SmallCap Momentum ETF (DWAS), Principal U.S. Small-Cap Multi-Factor ETF (PSC), Fidelity Small-Mid Cap Opportunities ETF (FSMO), VictoryShares US Small Mid Cap Value Momentum ETF (USVM), First Trust Small Cap Growth AlphaDEX Fund (FYC), iShares Russell 2000 Growth ETF (IWO) and JPMorgan BetaBuilders U.S. Small Cap Equity ETF (BBSC).

Evolent Health issued an update on its first quarter 2023 earnings guidance on Wednesday, February, 22nd. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $420.00 million-$440.00 million, compared to the consensus revenue estimate of $410.36 million.

12 employees have rated Evolent Health Chief Executive Officer Seth Blackley on Glassdoor.com. Seth Blackley has an approval rating of 100% among the company's employees. This puts Seth Blackley in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Evolent Health investors own include CA (CA), BlackRock (BLK), Universal Insurance (UVE), Endologix (ELGX), Advanced Micro Devices (AMD), Energy Transfer (ET), Chipotle Mexican Grill (CMG), Ford Motor (F), Cisco Systems (CSCO) and Heron Therapeutics (HRTX).

(EVH) raised $150 million in an IPO on Friday, June 5th 2015. The company issued 10,000,000 shares at $14.00-$16.00 per share. J.P. Morgan and Goldman Sachs acted as the underwriters for the IPO and Wells Fargo Securities, William Blair, SunTrust Robinson Humphrey and Leerink Partners were co-managers.

Evolent Health trades on the New York Stock Exchange (NYSE) under the ticker symbol "EVH."

Evolent Health's stock is owned by a number of institutional and retail investors. Top institutional investors include Point72 Asset Management L.P. (3.23%), Granahan Investment Management LLC (3.14%), Engaged Capital LLC (2.75%), Dimensional Fund Advisors LP (2.51%), Credit Suisse AG (2.32%) and Fred Alger Management LLC (1.87%). Insiders that own company stock include Cheryl Scott, Frank J Williams, Frank J Williams, John Paul Johnson, Jonathan Weinberg, Mary Bridget Duffy, Seth Blackley, Simon Maisey and Steve Tutewohl.
View institutional ownership trends.

Shares of EVH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of EVH stock can currently be purchased for approximately $31.05.

Evolent Health (NYSE:EVH) has a market capitalization of $3.45 billion and generates $1.35 billion in revenue each year. The technology company earns $-19,160,000.00 in net income (profit) each year or ($0.20) on an earnings per share basis.

The company employs 5,100 workers across the globe.

Evolent Health's mailing address is 800 NORTH GLEBE RD SUITE 500, ARLINGTON VA, 22203. The official website for the company is www.evolenthealth.com. The technology company can be reached via phone at (571) 389-6000, via email at investorrelations@evolenthealth.com, or via fax at 571-389-6001.